These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 29330143)

  • 1. Breast Cancer Targeting through Inhibition of the Endoplasmic Reticulum-Based Apoptosis Regulator Nrh/BCL2L10.
    Nougarede A; Popgeorgiev N; Kassem L; Omarjee S; Borel S; Mikaelian I; Lopez J; Gadet R; Marcillat O; Treilleux I; Villoutreix BO; Rimokh R; Gillet G
    Cancer Res; 2018 Mar; 78(6):1404-1417. PubMed ID: 29330143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum.
    Akl H; Vervloessem T; Kiviluoto S; Bittremieux M; Parys JB; De Smedt H; Bultynck G
    Biochim Biophys Acta; 2014 Oct; 1843(10):2240-52. PubMed ID: 24768714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor.
    Rong YP; Bultynck G; Aromolaran AS; Zhong F; Parys JB; De Smedt H; Mignery GA; Roderick HL; Bootman MD; Distelhorst CW
    Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14397-402. PubMed ID: 19706527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IRBIT controls apoptosis by interacting with the Bcl-2 homolog, Bcl2l10, and by promoting ER-mitochondria contact.
    Bonneau B; Ando H; Kawaai K; Hirose M; Takahashi-Iwanaga H; Mikoshiba K
    Elife; 2016 Dec; 5():. PubMed ID: 27995898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Bcl-2-IP
    Distelhorst CW
    Biochim Biophys Acta Mol Cell Res; 2018 Nov; 1865(11 Pt B):1795-1804. PubMed ID: 30053503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IP3R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP3R-derived peptide targeting the BH4 domain of Bcl-2.
    Akl H; Monaco G; La Rovere R; Welkenhuyzen K; Kiviluoto S; Vervliet T; Molgó J; Distelhorst CW; Missiaen L; Mikoshiba K; Parys JB; De Smedt H; Bultynck G
    Cell Death Dis; 2013 May; 4(5):e632. PubMed ID: 23681227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor.
    Rong YP; Barr P; Yee VC; Distelhorst CW
    Biochim Biophys Acta; 2009 Jun; 1793(6):971-8. PubMed ID: 19056433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Bcl-2 protein family member Bok binds to the coupling domain of inositol 1,4,5-trisphosphate receptors and protects them from proteolytic cleavage.
    Schulman JJ; Wright FA; Kaufmann T; Wojcikiewicz RJH
    J Biol Chem; 2013 Aug; 288(35):25340-25349. PubMed ID: 23884412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HA14-1 potentiates apoptosis in B-cell cancer cells sensitive to a peptide disrupting IP 3 receptor / Bcl-2 complexes.
    Akl H; La Rovere RM; Janssens A; Vandenberghe P; Parys JB; Bultynck G
    Int J Dev Biol; 2015; 59(7-9):391-8. PubMed ID: 26260683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel attenuates Bcl-2 resistance to apoptosis in breast cancer cells through an endoplasmic reticulum-mediated calcium release in a dosage dependent manner.
    Pan Z; Gollahon L
    Biochem Biophys Res Commun; 2013 Mar; 432(3):431-7. PubMed ID: 23415863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nrh L11R single nucleotide polymorphism, a new prediction biomarker in breast cancer, impacts endoplasmic reticulum-dependent Ca
    Duong MQ; Gadet R; Treilleux I; Borel S; Nougarède A; Marcillat O; Gonzalo P; Mikaelian I; Popgeorgiev N; Rimokh R; Gillet G
    Cell Death Dis; 2023 Jul; 14(6):392. PubMed ID: 37391438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcl-2 overexpression reduces cisplatin cytotoxicity by decreasing ER-mitochondrial Ca2+ signaling in SKOV3 cells.
    Xu L; Xie Q; Qi L; Wang C; Xu N; Liu W; Yu Y; Li S; Xu Y
    Oncol Rep; 2018 Mar; 39(3):985-992. PubMed ID: 29286126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.
    Lavik AR; Zhong F; Chang MJ; Greenberg E; Choudhary Y; Smith MR; McColl KS; Pink J; Reu FJ; Matsuyama S; Distelhorst CW
    Oncotarget; 2015 Sep; 6(29):27388-402. PubMed ID: 26317541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2's inhibition of apoptotic calcium signals.
    Rong YP; Aromolaran AS; Bultynck G; Zhong F; Li X; McColl K; Matsuyama S; Herlitze S; Roderick HL; Bootman MD; Mignery GA; Parys JB; De Smedt H; Distelhorst CW
    Mol Cell; 2008 Jul; 31(2):255-65. PubMed ID: 18657507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.
    Merino D; Lok SW; Visvader JE; Lindeman GJ
    Oncogene; 2016 Apr; 35(15):1877-87. PubMed ID: 26257067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double point mutation at residues Ile14 and Val15 of Bcl-2 uncovers a role for the BH4 domain in both protein stability and function.
    Monaco G; La Rovere R; Karamanou S; Welkenhuyzen K; Ivanova H; Vandermarliere E; Di Martile M; Del Bufalo D; De Smedt H; Parys JB; Economou A; Bultynck G
    FEBS J; 2018 Jan; 285(1):127-145. PubMed ID: 29131545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Constitutive IP
    Bittremieux M; La Rovere RM; Akl H; Martines C; Welkenhuyzen K; Dubron K; Baes M; Janssens A; Vandenberghe P; Laurenti L; Rietdorf K; Morciano G; Pinton P; Mikoshiba K; Bootman MD; Efremov DG; De Smedt H; Parys JB; Bultynck G
    Cell Death Differ; 2019 Mar; 26(3):531-547. PubMed ID: 29899382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
    Raha P; Thomas S; Thurn KT; Park J; Munster PN
    Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The BRCA1 tumor suppressor binds to inositol 1,4,5-trisphosphate receptors to stimulate apoptotic calcium release.
    Hedgepeth SC; Garcia MI; Wagner LE; Rodriguez AM; Chintapalli SV; Snyder RR; Hankins GD; Henderson BR; Brodie KM; Yule DI; van Rossum DB; Boehning D
    J Biol Chem; 2015 Mar; 290(11):7304-13. PubMed ID: 25645916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha-helical destabilization of the Bcl-2-BH4-domain peptide abolishes its ability to inhibit the IP3 receptor.
    Monaco G; Decrock E; Nuyts K; Wagner LE; Luyten T; Strelkov SV; Missiaen L; De Borggraeve WM; Leybaert L; Yule DI; De Smedt H; Parys JB; Bultynck G
    PLoS One; 2013; 8(8):e73386. PubMed ID: 24137498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.